Regeneron joins other Pharma Collosi in starting their own Venture Investment Arm.
Pfizer, Eli Lilly, Amgen, Bristol Myers Squibb, Astellas, and Novartis are all currently active in this space, with varying degrees of success.
With Regeneron, $500M over 5 years ain’t nothing to scoff at.
Drug development and venture investment, at a very high level, share similar risks, timelines, and associated ambiguities - and VC work also gets you early, insider access to potentially revolutionary tech and ideas.
For those with the dough and the stomach for it (which Big Pharma already has), VC is a solid move.
What do you think about this? With 2024 looking to be a banner year for biotech/pharma investment, are we going to see more Pharma-originating funds like this sprout up?
Article link in comments.
Doing cool things @ Harvard | 25u25 Boston & Philly | Co-Founder & CEO @ Circlez | Co-President Harvard Biotech | Researching neurodegeneration and rare disease experiences
4mo👏